The New York FBI has cracked another insider trading case, this time involving employees at the $7 billion Deerfield Management, a high-profile hedge fund whose managing partner warned in 2015 against investing in Valeant Pharmaceuticals due to its unsavory pricing practices. Insider trading allegations: Deerfield accused of accessing improper information In 2015, with Valeant stock trading over $100 per share, Deerfield’s New York-based Managing Partner Jim Flynn warned of the excesses at Valeant and its incisive drug pricing and distribution schemes. The stock price eventually collapsed under the weight of a federal investigation and is now trading at near $12…
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!
